There’s no sign that the wind­fall of cash drop­ping biotech’s way on Wall Street is abat­ing. Three more bio­phar­mas priced IPOs on Thurs­day and Fri­day morn­ing, rid­ing a his­toric boom with a $364 mil­lion pay­off.

Lon­don-based biotech Free­line Ther­a­peu­tics took home the li­on’s share of the cash with $159 mil­lion af­ter pric­ing 8,823,529 shares at $18 a pop. Check­mate Phar­ma­ceu­ti­cals, of Cam­bridge, MA, raised $75 mil­lion with an of­fer of 5 mil­lion shares at $15 — right at the mid­point of its range. And Arya Sci­ences Ac­qui­si­tion Corp III, the third in a se­ries from Per­cep­tive, priced 13,000,000 shares at $10 per share.

Drug­mak­ers are se­cur­ing big sums amid the pan­dem­ic boom, in­clud­ing AlloVir, which bagged $276 mil­lion from 16.3 mil­lion shares last week. Ini­tial­ly, the com­pa­ny had filed for a $100 mil­lion IPO. By June, all 23 new­ly pub­lic com­pa­nies had priced above their mid­point or up­sized their of­fer­ing.

And there’s more com­ing: Kymera Ther­a­peu­tics an­nounced plans to go pub­lic on Mon­day, when it filed for a $100 mil­lion IPO.

Check­mate ini­tial­ly filed for an IPO on Ju­ly 17, then raised its max­i­mum of­fer­ing price to $92 mil­lion in an amend­ed S-1 fil­ing. The im­muno-on­col­o­gy biotech is in­ves­ti­gat­ing its drug CMP-001 across mul­ti­ple can­cers, in­clud­ing melanoma and head and neck squa­mous cell car­ci­no­ma (HN­SCC), and says it will use the funds to ad­vance clin­i­cal tri­als. Bo­fA Se­cu­ri­ties, Jef­feries Group and BMO Cap­i­tal Mar­kets are man­ag­ing the deal.

CMP-001 us­es the im­mune sys­tem to its ad­van­tage, di­rect­ing ac­ti­vat­ed an­ti-tu­mor T cells to at­tack both the in­ject­ed tu­mor and tu­mors through­out the body. It’s been test­ed on more than 200 melanoma pa­tients to date, and based on clin­i­cal da­ta, the com­pa­ny be­lieves “there is an op­por­tu­ni­ty for CMP-001 to be de­vel­oped as a dif­fer­en­ti­at­ed im­muno-on­col­o­gy ther­a­py,” ac­cord­ing to the S-1 fil­ing.

Free­line ini­tial­ly filed for a $100 mil­lion IPO, with JP Mor­gan Se­cu­ri­ties LLC, Mor­gan Stan­ley & Co. and Ever­core Group as joint bookrun­ners. Its AAV gene-ther­a­py treat­ments tar­get he­mo­phil­ia A and B, Fab­ry dis­ease, and Type 1 Gauch­er dis­ease.

The biotech’s lead can­di­date, FLT180a, is cur­rent­ly in a Phase I/II tri­al for he­mo­phil­ia B. IPO funds will pro­pel the com­pa­ny’s pipeline, in­clud­ing Phase I/II tri­als for FLT180a and FLT190, a po­ten­tial drug to treat Fab­ry dis­ease.

SPACs (spe­cial pur­pose ac­qui­si­tion com­pa­nies) are ben­e­fit­ing from the boom, too. Once rare in the biotech world, they now rep­re­sent near­ly 35% of list­ings, Nas­daq’s Jay Heller told End­points last month.

Per­cep­tive Ad­vi­sors’ blank check com­pa­ny Arya III filed for a $143.7 mil­lion IPO on Ju­ly 21, and in­vestors are bet­ting on a prof­itable merg­er. In March, Arya I merged with biotech Im­mat­ics in a $252 mil­lion deal. Cerev­el Ther­a­peu­tics merged with Arya II in Ju­ly, ex­pect­ing to raise about $445 mil­lion to de­vel­op its pipeline.

The tumultuous ride for Orphazyme continued on Friday as the company announced that a pivotal trial for its lead drug arimoclomol failed yet again, this time in the treatment of ALS, seeding doubt in a drug that had recently been cleared by the FDA for priority review. The latest failure casts a darker shadow on the upcoming decision despite Orphazyme’s upbeat outlook.

In a statement, the Danish biotech announced that the drug did not meet its primary or secondary endpoints evaluating function and survival. But the company has not announced any data surrounding the failure, instead saying that it will publish the complete results later this year.

Pfizer and BioNTech said Friday that they’ve submitted a biologics license application to the FDA for full approval of their mRNA vaccine for those over the age of 16.

How long it will take the FDA to decide on the BLA will be set once it’s been formally accepted by the agency.

Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, previously told Endpoints News that the review of the BLA should take between three and four months, but it may be even faster than that.

One in a string of lawsuits targeting copay charity foundations, the DOJ has been hunting drugmaker Incyte for what prosecutors alleged was a kickback scheme to court patients. Now, Incyte is clearing its name.

Incyte will shell out $12.6 million to settle claims it funneled funds through a charity foundation to cover federal copays for patients taking its JAK inhibitor Jakafi, the DOJ said this week.